Pantoprazole use in the treatment of symptomatic (stress) gastro-duodenal ulcerations
- Authors: Loginov AF1, Kalinin AV1, Astashov VL1, Loginov AF1, Kalinin AV1, Astashov VL1
-
Affiliations:
- Issue: No 6 (2009)
- Pages: 50-56
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/276521
- ID: 276521
Cite item
Full Text
Abstract
Stress ulcers (SU) - symptomatic gastroduodenal erosions with stomach predominance. They arise due to extensive surgical interventions on the abdominal cavity organs and aorta, and myocardial infarction. The main pathogenetic mechanisms of SU are: ischemia of gastric and duodenum mucosa, hypovolemia, hypotension and apoplasmia; increase of ACTH, corticosteroids, catecholamines, and histamine production, which has an adverse effect on the mucous membrane, and enhancing the acid-peptic factor; gastroduodenal motility disturbanses (gastroparesis and enteroparesis, duodenogastric reflux). In modern therapy of SU, proton pump inhibitors with minimal potential for drug interactions having a dosage form for parenteral and oral administration are often used. SU management with pantoprazole, its efficacy for standard doses administration in comparison with other proton pump inhibitors are presented.
References
- Гастроэнтерология и гепатология: диагностика и лечение / Под ред. А.В. Калинина, А.И. Хазанова. М., 2006. 602 с.
- Di Fiore F, Lecleire S, Merle V, et al. Changes in characteristics and outcome of acute upper gastrointesninal haemorrhage: a comparision of epidemiology and practices between 1996 and 2000 in a multicentre French study. Eur J Gastroenterol Hepatol 2005;17:641-47.
- Никода В.В., Хартукова Н.Е. Применение ингибиторов протонной помпы в интенсивной терапии и реанимации // Фарматека. 2008. № 13. С. 10-16.
- Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М., 2001. 304 с.
- Лопина О.Д. Механизм действия ингибиторов протонного насоса // Российский журнал гастроэнтерологии, гепатологии и колопроктологии. 2002. № 2. Т. 12. С. 38-44.
- Heinze H, Preinfalk J, Athmann C, et al. Clinical efficacy and safety of pantoprasole in severe acid-peptic disease during up to 10 years maintenanse treatment. Gut 2003;52(Suppl. VI):A63.
- Brunner G, Harke U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 1994;8(Suppl. 1):59-64.
- Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34(5):185-94.
- Genta R, Magner D, D'Amico D. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients. Gastroenterology 2000;118:A16.
- Исаков В.А. Безопасность ингибиторов протонного насоса при длительном применении // Клиническая фармакология и терапия. 2004. Т. 13. № 1. С. 26-32.
- Blume H, Donath F, Warnke A, et al. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Safety 2006;29(9):769-84.
- Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996;34(5):185-94.
Supplementary files
